Although it is widely accepted that hyperphosphorylated tau is prone to aggregate formation and is pathogenic, a recent trial of tideglusib, a compound that targets the major tau kinase GSK-3β, failed to show clinical benefits in patients with AD13, raising the question of whether hyperphosphorylated tau is the sole cytotoxic source in AD. This evidence concerns the gene MAPT and Alzheimer disease.